Cover Image
市場調查報告書

EpiCast Report:登革熱的流行病學的預測

EpiCast Report: Dengue - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 301410
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:登革熱的流行病學的預測 EpiCast Report: Dengue - Epidemiology Forecast to 2023
出版日期: 2014年05月05日 內容資訊: 英文 42 Pages
簡介

登革熱是由黃病毒(單正鏈RNA病毒的一種)引起的發燒,大部分以埃及斑蚊(Aedes aegypti)為媒介。登革熱是感染人類的節肢動物媒介疾病中最常見的疾病之一。登革熱的重病度,從無症狀,到典型的登革熱,再到出血性登革熱(DHF)、登革熱休克症候群(DSS),有許多方面。在全球主要5個國家檢驗報告中確認、報告的登革熱的年度發病數量,2009∼2013年(平均值)為339,104件,預計2023年將達到339,104件(年複合成長率(CAGR)1.13%)。其中,巴西整體幾乎佔半數的發病數量(2023年達207,000件)。新的長期休眠型血清型的出現,成為今後感染擴大的推動因素。

本報告提供全球主要5個國家(巴西、印度、墨西哥、新加坡、泰國)的登革熱的發病情形和今後預測相關分析、疾病的特徵(風險要素和主要的共生病症等等)全球各國的趨勢、目前患病者的發病情形、今後10年的發病、患病數量的預測值等調查評估,並將其結果為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 概要
  • 近日出版的相關調查

第3章 流行病學

  • 疾病的背景
  • 風險要素和共生病症
  • 全世界的趨勢
    • 患病人數和全球各地的分佈情形
    • 登革熱的週期性、季節性模式
    • 登革熱的血清型
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法:
  • 登革熱的流行病學預測(今後11年份)
    • 檢驗確認、報告的發病數量
    • 檢驗確認、報告的發病數量(各年齡)
    • 檢驗確認、報告的發病數量(男女)
    • 檢驗確認、報告的發病數量(年齡已調整的)
  • 議論
    • 流行病學性的預測相關結論
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表一覽

目錄
Product Code: GDHCER062

Dengue fever is a febrile illness caused by a single-stranded flavirius most commonly transmitted by the Aedes aegypti mosquito. Dengue fever is one of the most prevalent arthropod-borne diseases affecting humans. The severity of dengue fever ranges from asymptomatic cases, to classic dengue fever, and to DHF or DSS.

GlobalData epidemiologists sourced government-based publications for the forecast of reported laboratory-confirmed dengue fever cases, including official national dengue reports, weekly surveillance reports, and reportable disease databases.

GlobalData epidemiologists forecast that laboratory-confirmed dengue cases in the 5MM will increase from an annual average of 304,608 cases from 2009-2013 to 339,104 cases in 2023 with an annual growth rate (AGR) of 1.13%. Brazil will have almost half the number of reported laboratory-confirmed dengue cases among the 5MM throughout the forecast period (207,000 cases in 2023). GlobalData epidemiologists believe that introductions of new or long-dormant dengue serotypes would be a significant driver in disease transmission in the 5MM during the next 10 years.

This report is based on laboratory-confirmed dengue cases reported by the national surveillance systems of the 5MM. Therefore, it should be used with the understanding that reported cases are a function of the dengue case burden in the country as well as the type and capacity of the dengue surveillance system.

This report provide a comprehensive analysis of dengue fever epidemiology in the 5MM, incorporating risk factors, disease burden, outbreak periodicity, serotype circulation pattern, regional variations in disease pattern, and age- and sex-specific distribution. The analysis is based on strong sources, including official national dengue reports, weekly surveillance reports, and reportable disease databases. GlobalData epidemiologists supplemented the national-level surveillance data with peer-reviewed regional studies. The analysis was also conducted using consistent methodology across the 5MM, thereby allowing meaningful comparison of the forecast numbers.

Scope

  • The Dengue EpiCast Report provides an overview of the dengue fever risk factors and comorbidities, global and historical epidemiology trends, and circulating serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) in five major markets (5MM) (Brazil, India, Mexico, Singapore, and Thailand). In addition, this report includes a 10-year epidemiology forecast for the reported laboratory-confirmed incident cases of dengue fever (including classic dengue fever, dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS)) for the 5MM. The reported laboratory-confirmed incident cases are segmented by sex and age (<1 year, 1 year, 2-14 years, 15-44 years, 45-64 years, and =65 years).
  • The dengue epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 5MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global dengue market.
  • Quantify patient populations in the global dengue market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for dengue pharmaceutical products in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. Incidence and Geographic Distribution
    • 3.3.2. Dengue Periodic and Seasonal Patterns
    • 3.3.3. Dengue Serotypes
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast of Dengue (2013-2023)
    • 3.5.1. Reported Laboratory-Confirmed Dengue Cases
    • 3.5.2. Sex-Specific Distribution of Reported Laboratory-Confirmed Dengue Cases
    • 3.5.3. Age-Specific Distribution of Reported Laboratory-Confirmed Dengue Cases
    • 3.5.4. Age-Standardized Incidence of Reported Laboratory-Confirmed Dengue
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors for Dengue Fever and Severe Dengue Fever (Dengue Hemorrhagic Fever and Dengue Shock Syndrome)
  • Table 2: Periodicity and Seasonality of Dengue Fever in the 5MM, 2003-2013
  • Table 3: 5MM, Circulating Dengue Virus Serotypes and Predominant Serotype, 2003-2013
  • Table 4: 5MM, Sources of Reported Laboratory-Confirmed Dengue Fever Data
  • Table 5: 5MM, Laboratory-Confirmed Dengue Cases, N (Col %), Men and Women, All Ages, Select Years 2009-2023
  • Table 6: 5MM, Sex-Specific Distribution of Reported Laboratory-Confirmed Dengue Cases, All Ages, Annual Average 2009-2013
  • Table 7: 5MM, Age-Specific Reported Laboratory-Confirmed Dengue Cases, All Ages, Annual Average 2009-2013

List of Figures

  • Figure 1: 5MM, Incidence Rate (Cases per 100,000 Population) of Reported Laboratory-Confirmed Dengue Cases (Including Classic Dengue Fever and DHF), Men and Women, All Ages, 2003-2013
  • Figure 2: 5MM, Reported Laboratory-Confirmed Dengue Cases, Men and Women, All Ages, 2014-2023
  • Figure 3: 5MM, Sex-Specific Distribution of Reported Laboratory-Confirmed Dengue Cases, All Ages, Annual Average 2009-2013
  • Figure 4: 5MM, Age-Specific Distribution of Reported Laboratory-Confirmed Dengue Cases, Men and Women, Annual Average 2009-2013
  • Figure 5: 5MM, Age-Standardized Incidence of Reported Laboratory-Confirmed Dengue Cases, All Ages, Annual Average 2009-2013
Back to Top